Side Effects of recombinant zoster (shingles) vaccine (rzv): A Synthesis of Findings from 3 Studies

  1. Home
  2. Side Effects of recombinant zoster (shingles) vaccine (rzv)
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of recombinant zoster (shingles) vaccine (rzv): A Synthesis of Findings from 3 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of recombinant zoster (shingles) vaccine (rzv): A Synthesis of Findings from 3 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Findings

The recombinant zoster vaccine (RZV) was licensed in the US in 2017 for the prevention of herpes zoster (HZ). 1 Real-world studies suggest that RZV is highly effective in preventing HZ across various populations, including adults aged 50 and older, and those aged 18 and older with immunodeficiency or immunosuppression. 1 The effectiveness was higher with two doses compared to one, particularly in elderly individuals and immunocompromised individuals. 1 The safety profile of RZV is generally consistent with that established in clinical trials. 1 RZV does not appear to increase the risk of disease flares in patients with immune-mediated diseases. 1 Around two-thirds of individuals received a second RZV dose within 2-6 months after the first dose. 1 These real-world studies collectively emphasize the high effectiveness of RZV against HZ, reaffirming its favorable benefit-risk profile.

3 evaluated the immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) when the first dose was co-administered with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged ≥50 years.

Reason for Side Effects

The recombinant zoster vaccine (RZV) is made using a portion of the gene from the varicella-zoster virus (VZV), which causes shingles. 1 When you get the RZV, your immune system makes proteins that are similar to those found in VZV, helping you build immunity to the virus. However, in some people, this immune response can be excessive, leading to side effects. 1

Common Side Effects

Injection Site Reactions

The most common side effect of RZV is an injection site reaction. 1 This may include pain, redness, and swelling. 1

Systemic Reactions

After receiving RZV, you may also experience systemic reactions, such as fever, headache, muscle aches, and fatigue. 1

Other Side Effects

In rare cases, serious side effects such as allergic reactions, Guillain-Barré syndrome, and encephalomyelitis can occur after receiving RZV. 1

Side Effect Management

Injection Site Reactions

If you are concerned about injection site reactions, talk to your doctor. 1 Your doctor may prescribe pain relievers or recommend cool compresses. 1

Systemic Reactions

If you are concerned about fever or headaches, talk to your doctor. 1 Your doctor may prescribe fever reducers or pain relievers. 1

Other Side Effects

If you experience a serious side effect such as an allergic reaction, contact your doctor immediately. 1

Comparison Between Studies

Commonalities

All three studies assessed the effectiveness and safety of RZV. 1 3

Differences

The 1 study collected real-world evidence to assess the effectiveness and safety of RZV. 1 The 3 study evaluated the immunogenicity and safety of RZV when the first dose was co-administered with PPSV23. 2 surveyed physician practices, attitudes, and knowledge regarding the recombinant zoster vaccine (RZV).

Application to Real Life

RZV is an effective vaccine for the prevention of shingles. 1 However, like all vaccines, there is a risk of side effects. 1 If you are considering getting RZV, it is important to talk to your doctor and understand the risks and benefits. 1

Limitations of Current Research

Real-world evidence regarding RZV is still limited. 1 Long-term safety data are still lacking. 1

Future Research Directions

Additional research is needed to assess the long-term safety and effectiveness of RZV. 1 Research is also needed on the optimal dosing schedule for RZV and its effectiveness in specific populations. 1

Conclusion

RZV is an effective vaccine for the prevention of HZ. 1 Real-world evidence supports the favorable benefit-risk profile of RZV. 1 However, like all vaccines, there is a risk of side effects. 1 If you are considering getting RZV, it is important to talk to your doctor and understand the risks and benefits. 1

Literature analysis of 3 papers
Positive Content
3
Neutral Content
0
Negative Content
0
Article Type
1
0
0
1
3
2.

Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine.

Author: HurleyLaura P, O'LearySean T, DoolingKathleen, AndersonTara C, CraneLori A, CataldiJessica R, BrtnikovaMichaela, BeatyBrenda L, GormanCarol, GuoAngela, LindleyMegan C, KempeAllison

Herpes zoster vaccination
RZV for immunocompromised

This article discusses the updated recommendations for recombinant zoster vaccine (RZV) by the Advisory Committee on Immunization Practice (ACIP), which now includes immunocompromised adults aged ≥19 years.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

3.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.

Author: MaréchalCéline, LalHimal, PoderAiri, FergusonMurdo, EnweonyeIgwebuike, HeinemanThomas C, HervéCaroline, RheaultPaul, TalliJaak, WautersDominique, OostvogelsLidia

Pneumococcal vaccine efficacy
Safe co-administration
Zoster vaccine efficacy
Vaccine side effects

Co-administration of RZV and PPSV23 in adults ≥50 years resulted in no immunologic interference. The vaccine response rate was >98% in both groups and humoral immune responses were non-inferior to sequential administration. The vaccine was safe and well tolerated.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.